Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 5, 2010, Pages 824-833

  Huke, Sabine ^a   Knollmann, Björn C ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Ca2+ handling; Conduction velocity; Energetic deficit; Mechanical stretch; Reentry arrhythmias; Sudden cardiac death

Indexed keywords

CALCIUM ION; CALCIUM;

ARRHYTHMOGENESIS; CARDIOMYOPATHY; DISEASE PREDISPOSITION; ENERGY METABOLISM; EXCITATION; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; HUMAN; MECHANICAL STRESS; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; HEART MUSCLE; METABOLISM; MICROFILAMENT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; DISEASE SUSCEPTIBILITY; HUMANS; MICROFILAMENTS; MYOCARDIUM; SIGNAL TRANSDUCTION; STRESS, MECHANICAL;

EID: 77951622995     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.01.011     Document Type: Review

References (192)

1. Ebashi S., Endo M. Calcium ion and muscle contraction. Prog Biophys Mol Biol 1968, 18:123-183.
2. Gomes A.V., Potter J.D., Szczesna-Cordary D. The role of troponins in muscle contraction. IUBMB Life. 2002, 54(6):323-333.
3. Huxley A.F. Muscle structure and theories of contraction. Prog Biophys Biophys Chem. 1957, 7:255-318.
4. Hibberd M.G., Jewell B.R. Calcium- and length-dependent force production in rat ventricular muscle. J Physiol. 1982, 329:527-540.
5. Kentish J.C., ter Keurs H.E., Ricciardi L., Bucx J.J., Noble M.I. Comparison between the sarcomere length-force relations of intact and skinned trabeculae from rat right ventricle. Influence of calcium concentrations on these relations. Circ Res. 1986, 58(6):755-768.
6. Patterson S.W., Piper H., Starling E.H. The regulation of the heart beat. J Physiol. 1914, 48(6):465-513.
7. Solaro R.J. Modulation of cardiac myofilament activity by protein phosphorylation 2002, Oxford University Press, New York.
8. Mope L., McClellan G.B., Winegrad S. Calcium sensitivity of the contractile system and phosphorylation of troponin in hyperpermeable cardiac cells. J Gen Physiol. 1980, 75(3):271-282.
9. Zhang R., Zhao J., Mandveno A., Potter J.D. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res 1995, 76(6):1028-1035.
10. Li L., Desantiago J., Chu G., Kranias E.G., Bers D.M. Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol. 2000, 278(3):H769-H779.
11. Haworth R.S., Cuello F., Herron T.J., Franzen G., Kentish J.C., Gautel M., et al. Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function. Circ Res 2004, 95(11):1091-1099.
12. Blanchard E.M., Solaro R.J. Inhibition of the activation and troponin calcium binding of dog cardiac myofibrils by acidic pH. Circ Res 1984, 55(3):382-391.
13. Fabiato A., Fabiato F. Effects of pH on the myofilaments and the sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles. J Physiol. 1978, 276:233-255.
14. Kentish J.C. The effects of inorganic phosphate and creatine phosphate on force production in skinned muscles from rat ventricle. J Physiol. 1986, 370:585-604.
15. Gao W.D., Atar D., Liu Y., Perez N.G., Murphy A.M., Marban E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997, 80(3):393-399.
16. Van Eyk J.E., Powers F., Law W., Larue C., Hodges R.S., Solaro R.J. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res 1998, 82(2):261-271.
17. Namba T., Takaki M., Araki J., Ishioka K., Akashi T., Zhao L.Y., et al. Ca2+ sensitivity of contractile machinery and Ca2+ handling energy. Simulation. Jpn Heart J. 1993, 34(5):601-616.
18. Nielsen-Kudsk J.E., Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure?. J Cardiovasc Pharmacol. 1995, 26(Suppl 1):S77-S84.
19. Solaro R.J., Gambassi G., Warshaw D.M., Keller M.R., Spurgeon H.A., Beier N., et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 1993, 73(6):981-990.
20. Wolska B.M., Kitada Y., Palmiter K.A., Westfall M.V., Johnson M.D., Solaro R.J. CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Am J Physiol 1996, 270(1 Pt 2):H24-H32.
21. Edes I., Kiss E., Kitada Y., Powers F.M., Papp J.G., Kranias E.G., et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995, 77(1):107-113.
22. Hajjar R.J., Schmidt U., Helm P., Gwathmey J.K. Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther. 1997, 280(1):247-254.
23. Webster K.A., Bodi I., McNamara J.P., Tracy M., Discher D.J., Bishopric N.H. Negative lusitropy and abnormal calcium handling in hypoxic cardiac myocytes exposed to the calcium-sensitizer EMD 53998. J Mol Cell Cardiol. 1993, 25(7):747-751.
24. Kivikko M., Antila S., Eha J., Lehtonen L., Pentikainen P.J. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002, 42(1):43-51.
25. Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkurinen K., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360(9328):196-202.
26. Slawsky M.T., Colucci W.S., Gottlieb S.S., Greenberg B.H., Haeusslein E., Hare J., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000, 102(18):2222-2227.
27. Kivikko M., Lehtonen L., Colucci W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003, 107(1):81-86.
28. Keren A., Syrris P., McKenna W.J. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008, 5(3):158-168.
29. Seggewiss H., Blank C., Pfeiffer B., Rigopoulos A. Hypertrophic cardiomyopathy as a cause of sudden death. Herz. 2009, 34(4):305-314.
30. Watkins H. Sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000, 342(6):422-424.
31. Moolman J.C., Corfield V.A., Posen B., Ngumbela K., Seidman C., Brink P.A., et al. Sudden death due to troponin T mutations. J Am Coll Cardiol. 1997, 29(3):549-555.
32. Varnava A., Baboonian C., Davison F., de Cruz L., Elliott P.M., Davies M.J., et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart. 1999, 82(5):621-624.
33. Watkins H., McKenna W.J., Thierfelder L., Suk H.J., Anan R., O'Donoghue A., et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995, 332(16):1058-1064.
34. Varnava A.M., Elliott P.M., Baboonian C., Davison F., Davies M.J., McKenna W.J. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001, 104(12):1380-1384.
35. Van Driest S.L., Ellsworth E.G., Ommen S.R., Tajik A.J., Gersh B.J., Ackerman M.J. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation. 2003, 108(4):445-451.
36. Gomes A.V., Potter J.D. Molecular and cellular aspects of troponin cardiomyopathies. Ann N Y Acad Sci 2004, 1015:214-224.
37. Knollmann B.C., Potter J.D. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2001, 11(5):206-212.
38. Tardiff J.C. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005, 10(3):237-248.
39. Gomes A.V., Potter J.D. Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Mol Cell Biochem 2004, 263(1-2):99-114.
40. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res. 1998 Jan 9-23; 82(1): 106-15.
41. Elliott K., Watkins H., Redwood C.S. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2000, 275(29):22069-22074.
42. Harada K., Potter J.D. Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. J Biol Chem. 2004, 279(15):14488-14495.
43. Harada K., Takahashi-Yanaga F., Minakami R., Morimoto S., Ohtsuki I. Functional consequences of the deletion mutation deltaGlu160 in human cardiac troponin T. J Biochem. 2000, 127(2):263-268.
44. Hernandez O.M., Szczesna-Cordary D., Knollmann B.C., Miller T., Bell M., Zhao J., et al. F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. J Biol Chem. 2005, 280(44):37183-37194.
45. Kruger M., Zittrich S., Redwood C., Blaudeck N., James J., Robbins J., et al. Effects of the mutation R145G in human cardiac troponin I on the kinetics of the contraction-relaxation cycle in isolated cardiac myofibrils. J Physiol. 2005, 564(Pt 2):347-357.
46. Morimoto S., Yanaga F., Minakami R., Ohtsuki I. Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol 1998, 275(1 Pt 1):C200-C207.
47. Nakaura H., Morimoto S., Yanaga F., Nakata M., Nishi H., Imaizumi T., et al. Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy. Am J Physiol 1999, 277(2 Pt 1):C225-C232.
48. Nakaura H., Yanaga F., Ohtsuki I., Morimoto S. Effects of missense mutations Phe110Ile and Glu244Asp in human cardiac troponin T on force generation in skinned cardiac muscle fibers. J Biochem. 1999, 126(3):457-460.
49. Szczesna D., Zhang R., Zhao J., Jones M., Guzman G., Potter J.D. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. J Biol Chem. 2000, 275(1):624-630.
50. Chandra M., Rundell V.L., Tardiff J.C., Leinwand L.A., De Tombe P.P., Solaro R.J. Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol. 2001, 280(2):H705-H713.
51. James J., Zhang Y., Osinska H., Sanbe A., Klevitsky R., Hewett T.E., et al. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000, 87(9):805-811.
52. Knollmann B.C., Blatt S.A., Horton K., de Freitas F., Miller T., Bell M., et al. Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem. 2001, 276(13):10039-10048.
53. Miller T., Szczesna D., Housmans P.R., Zhao J., de Freitas F., Gomes A.V., et al. Abnormal contractile function in transgenic mice expressing a familial hypertrophic cardiomyopathy-linked troponin T (I79N) mutation. J Biol Chem. 2001, 276(6):3743-3755.
54. Montgomery D.E., Tardiff J.C., Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol. 2001, 536(Pt 2):583-592.
55. Muthuchamy M., Pieples K., Rethinasamy P., Hoit B., Grupp I.L., Boivin G.P., et al. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res 1999, 85(1):47-56.
56. Sanbe A., James J., Tuzcu V., Nas S., Martin L., Gulick J., et al. Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy. Circulation. 2005, 111(18):2330-2338.
57. Tardiff J.C., Factor S.M., Tompkins B.D., Hewett T.E., Palmer B.M., Moore R.L., et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest. 1998, 101(12):2800-2811.
58. Kirschner S.E., Becker E., Antognozzi M., Kubis H.P., Francino A., Navarro-Lopez F., et al. Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol. 2005, 288(3):H1242-H1251.
59. Palmer B.M., Fishbaugher D.E., Schmitt J.P., Wang Y., Alpert N.R., Seidman C.E., et al. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol. 2004, 287(1):H91-H99.
60. Palmiter K.A., Tyska M.J., Haeberle J.R., Alpert N.R., Fananapazir L., Warshaw D.M. R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil. 2000, 21(7):609-620.
61. Witt C.C., Gerull B., Davies M.J., Centner T., Linke W.A., Thierfelder L. Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. J Biol Chem. 16 2001, 276(7):5353-5359.
62. Yang Q., Sanbe A., Osinska H., Hewett T.E., Klevitsky R., Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest. 1 1998, 102(7):1292-1300.
63. Szczesna-Cordary D., Guzman G., Zhao J., Hernandez O., Wei J., Diaz-Perez Z. The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice. J Cell Sci. 2005, 118(Pt 16):3675-3683.
64. Wang Y., Xu Y., Kerrick W.G., Guzman G., Diaz-Perez Z., Szczesna-Cordary D. Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations. J Mol Biol. 2006, 361(2):286-299.
65. van der Velden J., Merkus D., Klarenbeek B.R., James A.T., Boontje N.M., Dekkers D.H., et al. Alterations in myofilament function contribute to left ventricular dysfunction in pigs early after myocardial infarction. Circ Res 2004, 95(11):e85-e95.
66. de Waard M.C., van der Velden J., Bito V., Ozdemir S., Biesmans L., Boontje N.M., et al. Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ Res 2007, 100(7):1079-1088.
67. Billman G.E., Kukielka M. Effects of endurance exercise training on heart rate variability and susceptibility to sudden cardiac death: protection is not due to enhanced cardiac vagal regulation. J Appl Physiol. 2006, 100(3):896-906.
68. Billman G.E., Schwartz P.J., Stone H.L. The effects of daily exercise on susceptibility to sudden cardiac death. Circulation. 1984, 69(6):1182-1189.
69. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2001(1): CD001800.
70. Billman G.E. Cardiac autonomic neural remodeling and susceptibility to sudden cardiac death: effect of endurance exercise training. Am J Physiol Heart Circ Physiol. 2009, 297(4):H1171-H1193.
71. du Toit E., Hofmann D., McCarthy J., Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart. 2001, 86(1):81-87.
72. Flevari P., Parissis J.T., Leftheriotis D., Panou F., Kourea K., Kremastinos D.T. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006, 98(12):1641-1645.
73. van der Velden J., Papp Z., Zaremba R., Boontje N.M., de Jong J.W., Owen V.J., et al. Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 2003, 57(1):37-47.
74. Wolff M.R., Buck S.H., Stoker S.W., Greaser M.L., Mentzer R.M. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest. 1996, 98(1):167-176.
75. Brixius K., Savvidou-Zaroti P., Mehlhorn U., Bloch W., Kranias E.G., Schwinger R.H. Increased Ca2+-sensitivity of myofibrillar tension in heart failure and its functional implication. Basic Res Cardiol 2002, 97(Suppl 1):I111-I117.
76. Ardelt P., Dorka P., Jaquet K., Heilmeyer L.M., Kortke H., Korfer R., et al. Microanalysis and distribution of cardiac troponin I phospho species in heart areas. Biol Chem. 1998, 379(3):341-347.
77. Bodor G.S., Oakeley A.E., Allen P.D., Crimmins D.L., Ladenson J.H., Anderson P.A. Troponin I phosphorylation in the normal and failing adult human heart. Circulation. 1997, 96(5):1495-1500.
78. Messer A.E., Jacques A.M., Marston S.B. Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol. 2007, 42(1):247-259.
79. Marston S.B., de Tombe P.P. Troponin phosphorylation and myofilament Ca2+-sensitivity in heart failure: increased or decreased?. J Mol Cell Cardiol. 2008, 45(5):603-607.
80. Wolff M.R., Whitesell L.F., Moss R.L. Calcium sensitivity of isometric tension is increased in canine experimental heart failure. Circ Res 1995, 76(5):781-789.
81. Lamberts R.R., Hamdani N., Soekhoe T.W., Boontje N.M., Zaremba R., Walker L.A., et al. Frequency-dependent myofilament Ca2+ desensitization in failing rat myocardium. J Physiol. 2007, 582(Pt 2):695-709.
82. Baudenbacher F., Schober T., Pinto J.R., Sidorov V.Y., Hilliard F., Solaro R.J., et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest. 2008, 118(12):3893-3903.
83. Fentzke R.C., Buck S.H., Patel J.R., Lin H., Wolska B.M., Stojanovic M.O., et al. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol. 15 1999, 517(Pt 1):143-157.
84. White J., Lee J.A., Shah N., Orchard C.H. Differential effects of the optical isomers of EMD 53998 on contraction and cytoplasmic Ca2+ in isolated ferret cardiac muscle. Circ Res 1993, 73(1):61-70.
85. Dou Y., Arlock P., Arner A. Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. Am J Physiol Cell Physiol. 2007, 293(3):C1148-C1153.
86. Fedorov V.V., Lozinsky I.T., Sosunov E.A., Anyukhovsky E.P., Rosen M.R., Balke C.W., et al. Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts. Heart Rhythm. 2007, 4(5):619-626.
87. Kataoka A., Hemmer C., Chase P.B. Computational simulation of hypertrophic cardiomyopathy mutations in troponin I: influence of increased myofilament calcium sensitivity on isometric force, ATPase and [Ca2+]i. J Biomech. 2007, 40(9):2044-2052.
88. Knollmann B.C., Kirchhof P., Sirenko S.G., Degen H., Greene A.E., Schober T., et al. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res 2003, 92(4):428-436.
89. Ashrafian H., Redwood C., Blair E., Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 2003, 19(5):263-268.
90. Javadpour M.M., Tardiff J.C., Pinz I., Ingwall J.S. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest. 2003, 112(5):768-775.
91. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Second Edition ed. Dordrecht: KLUWER Academic Publishers; 2001.
92. Shannon T.R., Ginsburg K.S., Bers D.M. Reverse mode of the sarcoplasmic reticulum calcium pump and load-dependent cytosolic calcium decline in voltage-clamped cardiac ventricular myocytes. Biophys J 2000, 78(1):322-333.
93. Diaz M.E., Trafford A.W., Eisner D.A. The effects of exogenous calcium buffers on the systolic calcium transient in rat ventricular myocytes. Biophys J 2001, 80(4):1915-1925.
94. Trafford A.W., Diaz M.E., Eisner D.A. A novel, rapid and reversible method to measure Ca buffering and time-course of total sarcoplasmic reticulum Ca content in cardiac ventricular myocytes. Pflugers Arch 1999, 437(3):501-503.
95. Bassani R.A., Shannon T.R., Bers D.M. Passive Ca2+ binding in ventricular myocardium of neonatal and adult rats. Cell Calcium. 1998, 23(6):433-442.
96. Gryshchenko O., Huke S., Baudenbacher F., Potter J.D., Knollmann B.C. Ca2+ sensitizing troponin T mutations linked to hypertrophic cardiomyopathy increase apparent cytosolic Ca2+ binding. Biophys J 2009, 96:513a. Suppl.
97. Haikala H., Pollesello P. Calcium sensitivity enhancers. IDrugs. 2000, 3(10):1199-1205.
98. Powers F.M., Solaro R.J. Caffeine alters cardiac myofilament activity and regulation independently of Ca2+ binding to troponin C. Am J Physiol 1995, 268(6 Pt 1):C1348-C1353.
99. Takahashi R., Endoh M. Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. J Cardiovasc Pharmacol. 2001, 37(2):209-218.
100. Neumann J., Eschenhagen T., Grupp I.L., Haverich A., Herzig J.W., Hirt S., et al. Positive inotropic effects of the calcium sensitizer CGP 48506 in failing human myocardium. J Pharmacol Exp Ther. 1996, 277(3):1579-1585.
101. Puglisi J.L., Yuan W., Bassani J.W., Bers D.M. Ca(2+) influx through Ca(2+) channels in rabbit ventricular myocytes during action potential clamp: influence of temperature. Circ Res 1999, 85(6):e7-e16.
102. Wang S.Q., Song L.S., Lakatta E.G., Cheng H. Ca2+ signalling between single L-type Ca2+ channels and ryanodine receptors in heart cells. Nature 2001, 410(6828):592-596.
103. duBell W.H., Boyett M.R., Spurgeon H.A., Talo A., Stern M.D., Lakatta E.G. The cytosolic calcium transient modulates the action potential of rat ventricular myocytes. J Physiol 1991, 436:347-369.
104. London B. Cardiac arrhythmias: from (transgenic) mice to men. J Cardiovasc Electrophysiol. 2001, 12(9):1089-1091.
105. Cha Y.M., Gersh B.J., Maron B.J., Boriani G., Spirito P., Hodge D.O., et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2007, 18(5):483-487.
106. Pablo Kaski J., Tome Esteban M.T., Lowe M., Sporton S., Rees P., Deanfield J.E., et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007, 93(3):372-374.
107. Boersma L., Zetelaki Z., Brugada J., Allessie M. Polymorphic reentrant ventricular tachycardia in the isolated rabbit heart studied by high-density mapping. Circulation. 2002, 105(25):3053-3061.
108. Laurita K.R., Rosenbaum D.S. Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling. J Mol Cell Cardiol. 2008, 44(1):31-43.
109. Laurita K.R., Rosenbaum D.S. Cellular mechanisms of arrhythmogenic cardiac alternans. Prog Biophys Mol Biol 2008, 97(2-3):332-347.
110. Weiss J.N., Karma A., Shiferaw Y., Chen P.S., Garfinkel A., Qu Z. From pulsus to pulseless: the saga of cardiac alternans. Circ Res 26 2006, 98(10):1244-1253.
111. Goldhaber J.I., Xie L.H., Duong T., Motter C., Khuu K., Weiss J.N. Action potential duration restitution and alternans in rabbit ventricular myocytes: the key role of intracellular calcium cycling. Circ Res 2005, 96(4):459-466.
112. Sato D., Shiferaw Y., Garfinkel A., Weiss J.N., Qu Z., Karma A. Spatially discordant alternans in cardiac tissue: role of calcium cycling. Circ Res 2006, 99(5):520-527.
113. Watanabe M.A., Fenton F.H., Evans S.J., Hastings H.M., Karma A. Mechanisms for discordant alternans. J Cardiovasc Electrophysiol. 2001, 12(2):196-206.
114. Pastore J.M., Girouard S.D., Laurita K.R., Akar F.G., Rosenbaum D.S. Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. Circulation. 1999, 99(10):1385-1394.
115. H.Henry Rappel WJ.Dynamics of conduction blocks in a model of paced cardiac tissue. Phys Rev E Stat Nonlin Soft Matter Phys. May; 71 5 Pt 1 2005 051911.
116. Qu Z., Garfinkel A., Chen P.S., Weiss J.N. Mechanisms of discordant alternans and induction of reentry in simulated cardiac tissue. Circulation. 2000, 102(14):1664-1670.
117. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001, 103(15):2004-2013.
118. Mines G.R. On dynamic equilibrium in the heart. J Physiol. 1913, 46(4-5):349-383.
119. Girouard S.D., Pastore J.M., Laurita K.R., Gregory K.W., Rosenbaum D.S. Optical mapping in a new guinea pig model of ventricular tachycardia reveals mechanisms for multiple wavelengths in a single reentrant circuit. Circulation. 1996, 93(3):603-613.
120. Girouard S.D., Rosenbaum D.S. Role of wavelength adaptation in the initiation, maintenance, and pharmacologic suppression of reentry. J Cardiovasc Electrophysiol. 2001, 12(6):697-707.
121. January C.T., Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann N Y Acad Sci 1992, 644:23-32.
122. Sipido K.R., Bito V., Antoons G., Volders P.G., Vos M.A. Na/Ca exchange and cardiac ventricular arrhythmias. Ann N Y Acad Sci 2007, 1099:339-348.
123. Wu Y., Temple J., Zhang R., Dzhura I., Zhang W., Trimble R., et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation. 2002, 106(10):1288-1293.
124. Tanskanen A.J., Greenstein J.L., O'Rourke B., Winslow R.L. The role of stochastic and modal gating of cardiac L-type Ca2+ channels on early after-depolarizations. Biophys J 2005, 88(1):85-95.
125. Ingwall J.S., Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004, 95(2):135-145.
126. de Tombe P.P., Stienen G.J. Impact of temperature on cross-bridge cycling kinetics in rat myocardium. J Physiol. 2007, 584(Pt 2):591-600.
127. Frey N., Brixius K., Schwinger R.H., Benis T., Karpowski A., Lorenzen H.P., et al. Alterations of tension-dependent ATP utilization in a transgenic rat model of hypertrophic cardiomyopathy. J Biol Chem. Oct 6 2006, 281(40):29575-29582.
128. Sweeney H.L., Feng H.S., Yang Z., Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci U S A. 1998, 95(24):14406-14410.
129. Spindler M., Saupe K.W., Christe M.E., Sweeney H.L., Seidman C.E., Seidman J.G., et al. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest. 1998, 101(8):1775-1783.
130. Luedde M., Flogel U., Knorr M., Grundt C., Hippe H.J., Brors B., et al. Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy. J Mol Med. 2009, 87(4):411-422.
131. Jung W.I., Sieverding L., Breuer J., Hoess T., Widmaier S., Schmidt O., et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1998, 97(25):2536-2542.
132. Jung W.I., Hoess T., Bunse M., Widmaier S., Sieverding L., Breuer J., et al. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation 2000, 101(12):E121.
133. Crilley J.G., Boehm E.A., Blair E., Rajagopalan B., Blamire A.M., Styles P., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003, 41(10):1776-1782.
134. Grandis D.J., DelNido P.J., Koretsky A.P. Functional and energetic effects of the inotropic agents EMD-57033 and BAPTA on the isolated rat heart. Am J Physiol 1995, 269(2 Pt 1):C472-C479.
135. Holubarsch C., Hasenfuss G., Just H., Blanchard E., Mulieri L.A., Alpert N.R. Influence of the positive inotropic substance pimobendan (UD-CG 115 BS) on contractile economy of guinea pig papillary muscles. J Cardiovasc Pharmacol. 1989, 14(Suppl 2):S13-S17.
136. Onishi K., Sekioka K., Ishisu R., Abe Y., Tanaka H., Nakamura M., et al. MCI-154, a Ca2+ sensitizer, decreases the oxygen cost of contractility in isolated canine hearts. Am J Physiol 1997, 273(4 Pt 2):H1688-H1695.
137. Mori M., Takeuchi M., Takaoka H., Hata K., Hayashi Y., Yamakawa H., et al. Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts. J Am Coll Cardiol. 1997, 29(3):613-622.
138. Grandis D.J., MacGowan G.A., Koretsky A.P. Comparison of the effects of ORG 30029, dobutamine and high perfusate calcium on function and metabolism in rat heart. J Mol Cell Cardiol. 1998, 30(12):2605-2612.
139. MacGowan G.A. The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure. Cardiovasc Drugs Ther 2005, 19(3):203-210.
140. Teerlink J.R. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009 Feb, 21.
141. Tian R. Thermodynamic limitation for the sarcoplasmic reticulum Ca(2+)-ATPase contributes to impaired contractile reserve in hearts. Ann N Y Acad Sci 1998, 853:322-324.
142. Periasamy M., Huke S. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol. 2001, 33(6):1053-1063.
143. Bers D.M., Despa S. Na(+) transport in cardiac myocytes; implications for excitation-contraction coupling. IUBMB Life. 2009, 61(3):215-221.
144. Noma A. ATP-regulated K+channels in cardiac muscle. Nature. 1983 Sep 8-14; 305(5930): 147-8.
145. Nichols C.G., Ripoll C., Lederer W.J. ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction. Circ Res 1991, 68(1):280-287.
146. Wu T.J., Yashima M., Doshi R., Kim Y.H., Athill C.A., Ong J.J., et al. Relation between cellular repolarization characteristics and critical mass for human ventricular fibrillation. J Cardiovasc Electrophysiol. 1999, 10(8):1077-1086.
147. Whalley D.W., Wendt D.J., Starmer C.F., Rudy Y., Grant A.O. Voltage-independent effects of extracellular K+on the Na+current and phase 0 of the action potential in isolated cardiac myocytes. Circ Res 1994, 75(3):491-502.
148. Shivkumar K., Deutsch N.A., Lamp S.T., Khuu K., Goldhaber J.I., Weiss J.N. Mechanism of hypoxic K loss in rabbit ventricle. J Clin Invest. 1997, 100(7):1782-1788.
149. John S.A., Kondo R., Wang S.Y., Goldhaber J.I., Weiss J.N. Connexin-43 hemichannels opened by metabolic inhibition. J Biol Chem. 1999, 274(1):236-240.
150. John S., Cesario D., Weiss J.N. Gap junctional hemichannels in the heart. Acta Physiol Scand 2003, 179(1):23-31.
151. Kondo R.P., Wang S.Y., John S.A., Weiss J.N., Goldhaber J.I. Metabolic inhibition activates a non-selective current through connexin hemichannels in isolated ventricular myocytes. J Mol Cell Cardiol. 2000, 32(10):1859-1872.
152. Goodenough D.A., Paul D.L. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 2003, 4(4):285-294.
153. Solan J.L., Lampe P.D. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta 2005, 1711(2):154-163.
154. Clarke T.C., Williams O.J., Martin P.E., Evans W.H. ATP release by cardiac myocytes in a simulated ischaemia model: inhibition by a connexin mimetic and enhancement by an antiarrhythmic peptide. Eur J Pharmacol 2009, 605(1-3):9-14.
155. Thompson R.J., Zhou N., MacVicar B.A. Ischemia opens neuronal gap junction hemichannels. Science 2006, 312(5775):924-927.
156. Barth A.S., Tomaselli G.F. Cardiac metabolism and arrhythmias. Circ Arrhythm Electrophysiol. 2009, 2(3):327-335.
157. Neubauer S., Newell J.B., Ingwall J.S. Metabolic consequences and predictability of ventricular fibrillation in hypoxia. A 31P- and 23Na-nuclear magnetic resonance study of the isolated rat heart. Circulation. 1992, 86(1):302-310.
158. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989, 69(4):1049-1169.
159. Beeler G.W., Reuter H. Reconstruction of the action potential of ventricular myocardial fibres. J Physiol. 1977, 268(1):177-210.
160. Zingman L.V., Hodgson D.M., Bast P.H., Kane G.C., Perez-Terzic C., Gumina R.J., et al. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A. 2002, 99(20):13278-13283.
161. Suzuki M., Sasaki N., Miki T., Sakamoto N., Ohmoto-Sekine Y., Tamagawa M., et al. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest. 2002, 109(4):509-516.
162. Furukawa T., Kimura S., Furukawa N., Bassett A.L., Myerburg R.J. Role of cardiac ATP-regulated potassium channels in differential responses of endocardial and epicardial cells to ischemia. Circ Res 1991, 68(6):1693-1702.
163. Misier A.R., Opthof T., van Hemel N.M., Vermeulen J.T., de Bakker J.M., Defauw J.J., et al. Dispersion of 'refractoriness' in noninfarcted myocardium of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Circulation. 1995, 91(10):2566-2572.
164. Han J., Moe G.K. Nonuniform recovery of excitability in ventricular muscle. Circ Res 1964, 14:44-60.
165. Jansen J.A., van Veen T.A., de Bakker J.M., van Rijen H.V. Cardiac connexins and impulse propagation. J Mol Cell Cardiol. 2010, 48(1):76-82.
166. Sepp R., Severs N.J., Gourdie R.G. Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart. 1996, 76(5):412-417.
167. Solan J.L., Lampe P.D. Connexin43 phosphorylation: structural changes and biological effects. Biochem J 2009, 419(2):261-272.
168. Beardslee M.A., Lerner D.L., Tadros P.N., Laing J.G., Beyer E.C., Yamada K.A., et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res 2000, 87(8):656-662.
169. Turner M.S., Haywood G.A., Andreka P., You L., Martin P.E., Evans W.H., et al. Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circ Res 2004, 95(7):726-733.
170. Verrecchia F., Duthe F., Duval S., Duchatelle I., Sarrouilhe D., Herve J.C. ATP counteracts the rundown of gap junctional channels of rat ventricular myocytes by promoting protein phosphorylation. J Physiol. 1999, 516(Pt 2):447-459.
171. Jongsma H.J., Wilders R. Gap junctions in cardiovascular disease. Circ Res 2000, 86(12):1193-1197.
172. Poelzing S., Rosenbaum D.S. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol. 2004, 287(4):H1762-H1770.
173. Westermann D., Knollmann B.C., Steendijk P., Rutschow S., Riad A., Pauschinger M., et al. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail. 2006, 8(2):115-121.
174. Sirenko S.G., Potter J.D., Knollmann B.C. Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts-role of myofilament Ca2+ sensitivity increase. J Physiol. 2006, 575(Pt 1):201-213.
175. Ravens U. Mechano-electric feedback and arrhythmias. Prog Biophys Mol Biol 2003, 82(1-3):255-266.
176. Taggart Pl Lab M. Cardiac mechano-electric feedback and electrical restitution in humans. Prog Biophys Mol Biol 2008, 97(2-3):452-460.
177. Kaufmann R., Theophile U. Autonomously promoted extension effect in Purkinje fibers, papillary muscles and trabeculae carneae of rhesus monkeys. Pflugers Arch Gesamte Physiol Menschen Tiere. 1967, 297(3):174-189.
178. Franz M.R., Burkhoff D., Yue D.T., Sagawa K. Mechanically induced action potential changes and arrhythmia in isolated and in situ canine hearts. Cardiovasc Res 1989, 23(3):213-223.
179. Franz M.R., Cima R., Wang D., Profitt D., Kurz R. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation. 1992, 86(3):968-978.
180. Seo K., Inagaki M., Nishimura S., Hidaka I., Sugimachi M., Hisada T., et al. Structural heterogeneity in the ventricular wall plays a significant role in the initiation of stretch-induced arrhythmias in perfused rabbit right ventricular tissues and whole heart preparations. Circ Res 2010, 106(1):176-184.
181. Iribe G., Ward C.W., Camelliti P., Bollensdorff C., Mason F., Burton R.A., et al. Axial stretch of rat single ventricular cardiomyocytes causes an acute and transient increase in Ca2+ spark rate. Circ Res 2009, 104(6):787-795.
182. Tatsukawa Y., Kiyosue T., Arita M. Mechanical stretch increases intracellular calcium concentration in cultured ventricular cells from neonatal rats. Heart Vessels 1997, 12(3):128-135.
183. Jiang Y., Patterson M.F., Morgan D.L., Julian F.J. Basis for late rise in fura 2 R signal reporting [Ca2+]i during relaxation in intact rat ventricular trabeculae. Am J Physiol 1998, 274(5 Pt 1):C1273-C1282.
184. Kurihara S., Komukai K. Tension-dependent changes of the intracellular Ca2+ transients in ferret ventricular muscles. J Physiol. 1995, 489(Pt 3):617-625.
185. Allen D.G., Kentish J.C. The cellular basis of the length-tension relation in cardiac muscle. J Mol Cell Cardiol. 1985, 17(9):821-840.
186. Ter Keurs H.E., Wakayama Y., Miura M., Stuyvers B.D., Boyden P.A., Landesberg A. Spatial nonuniformity of contraction causes arrhythmogenic Ca2+ waves in rat cardiac muscle. Ann N Y Acad Sci 2005, 1047:345-365.
187. Wakayama Y., Miura M., Stuyvers B.D., Boyden P.A., ter Keurs H.E. Spatial nonuniformity of excitation-contraction coupling causes arrhythmogenic Ca2+ waves in rat cardiac muscle. Circ Res 2005, 96(12):1266-1273.
188. Kovacs M., Toth J., Hetenyi C., Malnasi-Csizmadia A., Sellers J.R. Mechanism of blebbistatin inhibition of myosin II. J Biol Chem. 2004, 279(34):35557-35563.
189. Allingham J.S., Smith R., Rayment I. The structural basis of blebbistatin inhibition and specificity for myosin II. Nat Struct Mol Biol 2005, 12(4):378-379.
190. Puglisi J.L., Bers D.M. LabHEART: an interactive computer model of rabbit ventricular myocyte ion channels and Ca transport. Am J Physiol Cell Physiol. 2001, 281(6):C2049-C2060.
191. Negroni J.A., Lascano E.C. Simulation of steady state and transient cardiac muscle response experiments with a Huxley-based contraction model. J Mol Cell Cardiol. 2008, 45(2):300-312.
192. Huke S., Venkataraman R., Sidorov V.Y., Baudenbacher F., Knollmann B.C. Decreased Connexin43 phosphorylation and reduced lateral conduction velocity contribute to arrhythmia risk in hypertrophic cardiomyopathy due to troponin T mutations. Circulation 2009, 120(Suppl. II):S682.